Ceftriaxone-sulbactam의 주요 호기성 및 혐기성 임상 분리균주에 대한 시험관내 항균력
In Vitro Activities of Ceftriaxone-Sulbactam against Major Aerobic and Anaerobic Bacteria from Clinical Samples
0
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: β-lactam antibiotics are one of the most common antimicrobial agents. However, the increasing of β-lactamase-producing bacteria makes these agents less useful. Therefore, agents stable for β-lactamase have been developed. This study was conducted to determine the activities of the combination agent ceftriaxone-sulbactam and to compare its activities with other agents. Methods: A total of 437 clinical isolates of aerobic and anaerobic bacteria were collected in Severance Hospital from 2007 to 2011. Using 23 antimicrobial agents, antimicrobial susceptibility tests were performed using the Clinical and Laboratory Standards Institute (CLSI) agar dilution method. Results: The minimal inhibitory concentrations (MICs) of ceftriaxone and ceftriaxone-sulbactam were similar to or lower than those of other β-lactam antibiotics for methicillin-susceptible Staphylococcus aureus (MSSA), Streptococcus pneumoniae, S. pyogenes, and viridans group streptococci. For Moraxella catarrhalis, Neisseria gonorrhoeae, Haemophilus influenzae, and H. parainfluenzae, ceftriaxone and the ceftriaxone-sulbactam combination also show low MIC_(50) and MIC_(90). For extended-spectrum β-lactamase (ESBL)-producing E. coli, the MICs of ceftriaxone-sulbactam were lower than those of other cephalosporins. Among the anaerobes, ceftriaxone-sulbactam showed good activity compared to ceftriaxone alone for the Bacteroides fragilis group, B. thetaiotaomicron, other Bacteroides sp., Prevotella sp., and Porphyromonas sp. Conclusions: Ceftriaxone-sulbactam showed good antimicrobial activity and thus is useful for the treatment of infections by MSSA, S. pneumoniae,S. pyogenes, viridans group streptococci, M. catarrhalis, N. gonorrhoeae, H. influenzae, H. parainfluenzae, E. coli, and K. pneumoniae, B. fragilis group, B. thetaiotaomicron, other Bacteroides sp., Prevotella sp., and Porphyromonas sp.
Abstract
Background: β-lactam antibiotics are one of the most common antimicrobial agents. However, the increasing of β-lactamase-producing bacteria makes these agents less useful. Therefore, agents stable for β-lactamase have been developed. This study was conducted to determine the activities of the combination agent ceftriaxone-sulbactam and to compare its activities with other agents. Methods: A total of 437 clinical isolates of aerobic and anaerobic bacteria were collected in Severance Hospital from 2007 to 2011. Using 23 antimicrobial agents, antimicrobial susceptibility tests were performed using the Clinical and Laboratory Standards Institute (CLSI) agar dilution method. Results: The minimal inhibitory concentrations (MICs) of ceftriaxone and ceftriaxone-sulbactam were similar to or lower than those of other β-lactam antibiotics for methicillin-susceptible Staphylococcus aureus (MSSA), Streptococcus pneumoniae, S. pyogenes, and viridans group streptococci. For Moraxella catarrhalis, Neisseria gonorrhoeae, Haemophilus influenzae, and H. parainfluenzae, ceftriaxone and the ceftriaxone-sulbactam combination also show low MIC_(50) and MIC_(90). For extended-spectrum β-lactamase (ESBL)-producing E. coli, the MICs of ceftriaxone-sulbactam were lower than those of other cephalosporins. Among the anaerobes, ceftriaxone-sulbactam showed good activity compared to ceftriaxone alone for the Bacteroides fragilis group, B. thetaiotaomicron, other Bacteroides sp., Prevotella sp., and Porphyromonas sp. Conclusions: Ceftriaxone-sulbactam showed good antimicrobial activity and thus is useful for the treatment of infections by MSSA, S. pneumoniae,S. pyogenes, viridans group streptococci, M. catarrhalis, N. gonorrhoeae, H. influenzae, H. parainfluenzae, E. coli, and K. pneumoniae, B. fragilis group, B. thetaiotaomicron, other Bacteroides sp., Prevotella sp., and Porphyromonas sp.
참고문헌 (14)
- Livermore DM, "ß-Lactamases in laboratory and clinical resistance", Clin Microbiol Rev, 8, pp.557~584 (1995)
- Nordmann P, "Trends in ß-lactam resistance among Enterobacteriaceae", Clin Infect Dis, 27, pp.100~106 (1998)
- Moellering RC Jr, "Meeting the challenges of ß -lactamases", J Antimicrob Chemother, 31, pp.1~8 (1993)
- Sutherland R, "ß-lactam", ß-lactamase inhibitor combinations: development, antibacterial activity and clinical applications, 1995, pp.23, 191~200
- Bhattacharjee A, "Role of ß-lactamase inhibitors in enterobacterial isolates producing extended-spectrum ßlactamases", J Antimicrob Chemother, 61, pp.309~314 (2008)
- Fantin B, "Activity of sulbactam in combination with ceftriaxone in vitro and in experimental endocarditis caused by Escherichia coli producing SHV-2-like ß-lactamase", Antimicrob Agents Chemother, 34, pp.581~586 (1990)
- Caron F, "Ceftriaxone-sulbactam combination in rabbit endocarditis caused by a strain of Klebsiella pneumoniae producing extended-broad-spectrum TEM-3 ß-lactamase", Antimicrob Agents Chemother, 34, pp.2070~2074 (1990)
- Ferreira L, "Direct identification of urinary tract pathogens from urine samples by matrix-assisted laser desorption ionization-time of flight mass spectrometry", J Clin Microbiol, 48, pp.2110~2115 (2010)
- Moretti M, "CLSI EP17-A protocol: a useful tool for better understanding the low end performance of total prostate-specific antigen assays", Clin Chim Acta, 412, pp.1143~1145 (2011)
- Rice LB, "Resistance to cefoperazone-sulbactam in Klebsiella pneumoniae: evidence for enhanced resistance resulting from the coexistence of two different resistance mechanisms", Antimicrob Agents Chemother, 37, pp.1061~1064 (1993)
- Kaczmarek FS, "Genetic and molecular characterization of ß-lactamase-negative ampicillin-resistant Haemophilus influenzae with unusually high resistance to ampicillin", Antimicrob Agents Chemother, 48, pp.1630~1639 (2004)
- Kyungwon Lee, "Metallo-β-Lactamase-Producing Pseudomonas spp. in Korea: High Prevalence of Isolates with VIM-2 Type and Emergence of Isolates with IMP-1 Type", Yonsei Medical Journal, 50(3), pp.335~339 (2009), 연세대학교의과대학
- Nordmann P, "Emerging carbapenemases in Gram-negative aerobes", Clin Microbiol Infect, 8, pp.321~331 (2002)
- Michalopoulos A, "Treatment of Acinetobacter infections", Expert Opin Pharmacother, 11, pp.779~788 (2010)